Literature DB >> 25065902

Neurodevelopmental origin of cognitive impairment in schizophrenia.

E Bora1.   

Abstract

Cognitive impairment is a common feature of schizophrenia; however, its origin remains controversial. Neurodevelopmental abnormalities clearly play a role in pre-morbid cognitive dysfunction in schizophrenia, yet many authors believe that schizophrenia is characterized by illness-related cognitive decline before and after onset of the psychosis that can be the result of neurodegenerative changes. The main reasons behinds such arguments include, first, the evidence showing that effect sizes of the cognitive deficits in subjects who develop adult schizophrenia gradually increase in the first two decades of life and, second, the fact that there is functional decline in many patients with schizophrenia over the years. In this Editorial, I argue that current evidence suggests that illness-related cognitive impairment is neurodevelopmental in origin and characterized by slower gain (developmental lag) but not cognitive decline continuing throughout the first two decades of life. I introduce a model suggesting that neurodevelopmental abnormality can in fact explain the course of cognitive dysfunction and variations in the trajectory of functional decline throughout the life in individuals with schizophrenia. In this model, the severity of underlying neurodevelopmental abnormality determines the age that cognitive deficits first become apparent and contributes to the cognitive reserve of the individual. Interaction of neurodevelopmental abnormality with clinical symptoms, especially negative symptoms and aging, vascular changes, psychological and iatrogenic factors contributes to the heterogeneity of the functional trajectory observed in this disorder.

Entities:  

Mesh:

Year:  2014        PMID: 25065902     DOI: 10.1017/S0033291714001263

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  25 in total

1.  Neurocognition and Duration of Psychosis: A 10-year Follow-up of First-Episode Patients.

Authors:  Bjørn Rishovd Rund; Helene Eidsmo Barder; Julie Evensen; Ulrik Haahr; Wenche ten Velden Hegelstad; Inge Joa; Jan Olav Johannessen; Johannes Langeveld; Tor Ketil Larsen; Ingrid Melle; Stein Opjordsmoen; Jan Ivar Røssberg; Erik Simonsen; Kjetil Sundet; Per Vaglum; Thomas McGlashan; Svein Friis
Journal:  Schizophr Bull       Date:  2015-06-21       Impact factor: 9.306

2.  Positive and general psychopathology associated with specific gray matter reductions in inferior temporal regions in patients with schizophrenia.

Authors:  Eva Mennigen; Wenhao Jiang; Vince D Calhoun; Theo G M van Erp; Ingrid Agartz; Judith M Ford; Bryon A Mueller; Jingyu Liu; Jessica A Turner
Journal:  Schizophr Res       Date:  2019-02-26       Impact factor: 4.939

3.  Extra-axial Cerebrospinal Fluid Relationships to Infant Brain Structure, Cognitive Development, and Risk for Schizophrenia.

Authors:  Veronica A Murphy; Mark D Shen; Sun Hyung Kim; Emil Cornea; Martin Styner; John H Gilmore
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2020-04-01

Review 4.  GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.

Authors:  Meng-Yi Xu; Albert H C Wong
Journal:  Acta Pharmacol Sin       Date:  2018-03-22       Impact factor: 6.150

5.  The impact of psychosis on the course of cognition: a prospective, nested case-control study in individuals at clinical high-risk for psychosis.

Authors:  R E Carrión; D McLaughlin; A M Auther; R Olsen; C U Correll; B A Cornblatt
Journal:  Psychol Med       Date:  2015-07-14       Impact factor: 7.723

6.  Elevated TREM2 mRNA expression in leukocytes in schizophrenia but not major depressive disorder.

Authors:  Yuta Yoshino; Kentaro Kawabe; Kiyohiro Yamazaki; Shinya Watanabe; Shusuke Numata; Yoko Mori; Taku Yoshida; Junichi Iga; Tetsuro Ohmori; Shu-Ichi Ueno
Journal:  J Neural Transm (Vienna)       Date:  2016-04-29       Impact factor: 3.575

7.  Interrelationships Between BDNF, Superoxide Dismutase, and Cognitive Impairment in Drug-Naive First-Episode Patients With Schizophrenia.

Authors:  Mei Hong Xiu; Zezhi Li; Da Chun Chen; Song Chen; Maile E Curbo; Hanjing Emily Wu; Yong Sheng Tong; Shu Ping Tan; Xiang Yang Zhang
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

Review 8.  Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective.

Authors:  Julia M Sheffield; Nicole R Karcher; Deanna M Barch
Journal:  Neuropsychol Rev       Date:  2018-10-20       Impact factor: 7.444

9.  The relationship between childhood trauma and schizophrenia in the Genomics of Schizophrenia in the Xhosa people (SAX) study in South Africa.

Authors:  Sumaya Mall; Jonathan M Platt; Henk Temmingh; Eustasius Musenge; Megan Campbell; Ezra Susser; Dan J Stein
Journal:  Psychol Med       Date:  2019-08-07       Impact factor: 7.723

10.  Association of Lipid Peroxidation and Brain-Derived Neurotrophic Factor with Executive Function in Adolescent Bipolar Disorder.

Authors:  Dwight F Newton; Melanie R Naiberg; Ana C Andreazza; Gustavo Scola; Daniel P Dickstein; Benjamin I Goldstein
Journal:  Psychopharmacology (Berl)       Date:  2016-12-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.